Stem Cell Therapeutics Corp. Announces the Completion of the 90 Day Endpoint Period for the Last Patient Enrolled in the Modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA -- (Marketwire) -- 04/26/10 -- Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) is pleased to announce today that the 90- day follow up period for the last patient enrolled in the modified REGENESIS- Phase IIb stroke trial has been reached. The modified REGENESIS- Phase IIb trial, a placebo controlled, double blinded, 3:1 randomized clinical study, enrolled 96 patients with acute ischemic stroke between August 2009 and January 24, 2010. This point in the trial is a major milestone, as it marks the completion of the patient assessment period and the beginning of the process of compilation, data analysis and reporting of top-line primary endpoint results for this key Phase IIb clinical trial of NTx®-265 in acute stroke.
Dr. Alan Moore, President and CEO, commented as follows:
"With the last patient completing their 90-day observation endpoint, the modified REGENESIS- Phase IIb stroke trial enters into the exciting stage of data analysis and the reporting of top-line results. This exhilarating period in the Company's development is the culmination of solid support from the Company's shareholders, management and research and development team. SCT looks forward with great anticipation to the soon to be announced top-line results of the modified REGENESIS- trial as this truly marks a key milestone in the development of this new therapy for stroke patients. With enrollment of the modified Phase IIb stroke trial ended and data analysis commencing top-line results are expected within the next 4 weeks, significantly earlier than the "end of Q2" target that we previously discussed."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
403-245-5495 ext.224
amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Angelika Goncalves DaSilva
Operations Manager
403-245-5495 ext. 221
adasilva@stemcellthera.com
www.stemcellthera.com
< Return to Press Releases
Articles appearing above are picked up from MarketWire's feed. Stories from this feed are submitted by companies, edited and rereleased as a service of MarketWire.
Sign up for FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more
Companies mentioned
•Cell Therapeutics Corp.
